Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Deloitte
Chinese Patent Office
Merck
US Department of Justice
Federal Trade Commission
QuintilesIMS
Fish and Richardson
Daiichi Sankyo

Generated: July 17, 2018

DrugPatentWatch Database Preview

Rivastigmine - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for rivastigmine and what is the scope of rivastigmine freedom to operate?

Rivastigmine
is the generic ingredient in three branded drugs marketed by Novartis, Alvogen Malta, Mylan Technologies, Ajanta Pharma Ltd, Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Cadila Pharms Ltd, Dr Reddys Labs Inc, Macleods Pharms Ltd, Orchid Hlthcare, Sun Pharm Inds Ltd, and Watson Labs, and is included in fifteen NDAs. There are two patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Rivastigmine has thirty-seven patent family members in twenty-seven countries.

There are thirty-two drug master file entries for rivastigmine. Six suppliers are listed for this compound. There is one tentative approval for this compound.
Pharmacology for rivastigmine
Medical Subject Heading (MeSH) Categories for rivastigmine
Synonyms for rivastigmine
(R)-Rivastigmine (Rivastigmine EP Impurity D)
(S)-1-(3-((ethyl(methyl)carbamoyl)oxy)phenyl)-N,N-dimethylethanamine
(S)-3-(1-(dimethylamino)ethyl)phenyl ethyl(methyl)carbamate
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
(S)-3-[1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methyl-carbamate
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
[3-[(1S)-1-dimethylaminoethyl]phenyl] N-ethyl-N-methylcarbamate
101R548
123441-03-2
2,3-dihydroxybutanedioic acid; 3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate; Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl N-methyl carbamate
3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate
3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate
AB01275472_02
AB01275472_03
AB01275472-01
AB1004572
ABP001082
AC-8250
AC1L2U92
AJ-08211
AK161672
AKOS015896334
AN-1074
API0008913
BC225687
BDBM10620
BDBM11682
BIDD:GT0316
C-23825
C11766
Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-
CC-34273
CCG-221197
CHEBI:8874
CHEMBL636
CS-0946
D03822
D0WY5Q
DB00989
DR000673
DTXSID7023564
EBD46209
ENA 713 free base
ENA-713
Ethyl-methyl-carbamic acid 3-((R)-1-dimethylamino-ethyl)-phenyl ester
Ethyl-methyl-carbamic acid 3-((S)-1-dimethylamino-ethyl)-phenyl ester
Ethyl-methyl-carbamic acid 3-(1-dimethylamino-ethyl)-phenyl ester
Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
Exelon
Exelon Patch
Exelon; Rivastigmine hydrogen tartrate; 3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate; Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester; 3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylc
F10108
FT-0651952
GTPL6602
HMS2089H18
HY-17368
I06-2037
KS-00000H18
LS-172571
m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
MFCD00871496
MLS003876822
MolPort-003-666-662
NCGC00167531-03
Nimvastid
OR210090
PKI06M3IW0
Prometax
Prometax (TN)
Rivastigmine (JAN/USAN/INN)
Rivastigmine (transdermal patch)
Rivastigmine [USAN:INN:BAN:JAN]
Rivastigmine [USAN:INN]
rivastigmine hexal
Rivastigmine Teva
Rivastigmine Transdermal System
Rivastigmine.tartrate
RL06150
S-Rivastigmine
S4687
SCHEMBL2764
SDZ 212-713
SDZ-212-713
SDZ-ENA-713
SMR002203623
ST24049123
UNII-PKI06M3IW0
W-200966
W-5183
XSVMFMHYUFZWBK-NSHDSACASA-N
Y9059
ZINC4413
Tentative approvals for RIVASTIGMINE
Applicant Application No. Strength Dosage Form
➤ Sign Up➤ Sign Up2MG/MLSOLUTION; ORAL

US Patents and Regulatory Information for rivastigmine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Ltd RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 077131-004 Oct 22, 2007 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-001 Jul 6, 2007 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Cadila Pharms Ltd RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 203844-001 Feb 13, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Aurobindo Pharma Ltd RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 204572-004 Mar 25, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for rivastigmine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-002 Jul 6, 2007 ➤ Sign Up ➤ Sign Up
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-002 Jul 6, 2007 ➤ Sign Up ➤ Sign Up
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-001 Jul 6, 2007 ➤ Sign Up ➤ Sign Up
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-001 Jul 6, 2007 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for rivastigmine

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
80031 Netherlands ➤ Sign Up PRODUCT NAME: RIVASTIGMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER RIVASTIGMINE WATERSTOFTAR- TRAAT; REGISTRATION NO/DATE: EU/1/98/066/001 - EU/1/98/066/012 19980512
C/GB98/041 United Kingdom ➤ Sign Up PRODUCT NAME: RIVASTIGMINE, AS FREE BASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 5427501 19970731; CH 5427502 19970731; CH 5427503 19970731; CH 5427504 19970731; CH 5427505 19970731; CH 5427506 19970731; UK EU/1/98/066/001 19980512; UK EU/1/98/066/002 19980512; UK EU/1/98/066/003 19980512; UK EU/1/98/066/004 19980512; UK EU/1/98/066/005 19980512; UK EU/1/98/066/006 19980512; UK EU/1/98/092/023 19980512; UK EU/1/98/092/024 19980512; UK EU/1/98/092/025 19980512; UK EU/1/98/092/026 19980512; UK EU/1/98/066/025 19980512; UK EU/1/98/066/026 19980512; UK EU/1/98/092/019 19980512; UK EU/1/98/092/020 19980512; UK EU/1/98/092/021 19980512; UK EU/1/98/092/022 19980512; UK EU/1/98/0
C0038 Belgium ➤ Sign Up PRODUCT NAME: RIVASTIGMINE; NAT. REGISTRATION NO/DATE: EU/1/98/066/001 19980512; FIRST REGISTRATION: CH 54275 01 19970731
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Accenture
Argus Health
Fuji
Daiichi Sankyo
Colorcon
Healthtrust
AstraZeneca
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.